Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.46 |
| ▸ | TP53 | P04637 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | RAB9A | P51151 | 3/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15939755 | 0.75 | CYP3A4 (0.68) | LMNAHSD17B10CYP3A4MAPK1SMN1; SMN2 | |
| SCHEMBL13584825 | 0.67 | RAB9A (0.39) | LMNAGAATP53TSHRSMN1; SMN2 | |
| SCHEMBL21303128 | 0.64 | RAB9A (0.55) | LMNAGAAHSD17B10L3MBTL1TP53 | |
| SCHEMBL9955496 | 0.64 | SLC12A5 (0.49) | LMNAGAATSHRSMN1; SMN2KDM4E | |
| SCHEMBL3978058 | 0.64 | — | — | |
| SCHEMBL11903628 | 0.63 | SMN1; SMN2 (0.36) | LMNAHSD17B10SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL29067361 | 0.62 | L3MBTL1 (0.42) | GAAL3MBTL1TP53SMN1; SMN2ALDH1A1 | |
| Lithium SCHEMBL30570038 | 0.62 | L3MBTL1 (0.42) | GAAL3MBTL1TP53SMN1; SMN2ALDH1A1 | |
| SCHEMBL21222557 | 0.61 | TP53 (0.66) | GAAL3MBTL1TP53SMN1; SMN2KDM4E | |
| SCHEMBL11623906 | 0.60 | CYP3A4 (0.37) | LMNAGAAHSD17B10TP53CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2968324-B1 | SUBSTITUTED PYRIDAZINONE DERIVATIVES AS PDE10 INHIBITORS | MERCK SHARP & DOHME (US) | 2018-04-18 | — | — | EP | disclosed |
| US-9353104-B2 | Substituted pyridizinone derivatives as PDE10 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-05-31 | — | — | US | disclosed |
| EP-2748151-B1 | PYRIMIDINE PDE10 INHIBITORS | MERCK SHARP & DOHME (US) | 2016-03-16 | — | — | EP | disclosed |
| US-20160016947-A1 | SUBSTITUTED PYRIDIZINONE DERIVATIVES AS PDE10 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-01-21 | — | — | US | disclosed |
| EP-2968324-A1 | SUBSTITUTED PYRIDIZINONE DERIVATIVES AS PDE10 INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2016-01-20 | — | — | EP | disclosed |
| US-9062059-B2 | Pyrimidine PDE10 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-06-23 | — | — | US | disclosed |
| WO-2014150114-A1 | SUBSTITUTED PYRIDIZINONE DERIVATIVES AS PDE10 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014139150-A1 | SUBSTITUTED PYRIDIZINONE DERIVATIVES AS PDE10 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-09-18 | — | — | WO | disclosed |
| US-20140228368-A1 | PYRIMIDINE PDE10 INHIBITORS | MERCK SHARP & DOHME LLC | 2014-08-14 | — | — | US | disclosed |
| EP-2748151-A1 | PYRIMIDINE PDE10 INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2014-07-02 | — | — | EP | disclosed |
| WO-2013028590-A1 | PYRIMIDINE PDE10 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-02-28 | — | — | WO | disclosed |
| EP-1296938-A1 | CYCLOPENTYL-SUBSTITUTED GLUTARAMIDE DERIVATIVES AS INHIBITORS OF NEUTRAL ENDOPEPTIDASE | Pfizer Limited (GB) | 2003-04-02 | — | — | EP | disclosed |
| US-20020052370-A1 | Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase | PFIZER, INC. | 2002-05-02 | — | — | US | disclosed |
| WO-2002002513-A1 | CYCLOPENTYL-SUBSTITUTED GLUTARAMIDE DERIVATIVES AS INHIBITORS OF NEUTRAL ENDOPEPTIDASE | PFIZER LIMITED (GB) | 2002-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140228368-A1 | PYRIMIDINE PDE10 INHIBITORS | PDE12, PDE10A, PDE11A | LMNA 4774/4885GAA 222/4885HSD17B10 296/4885 |
| US-20020052370-A1 | Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase | ENGASE, ENPEP, CPN1 | LMNA 2711/4885GAA 26/4885HSD17B10 839/4885 |
| US-20160016947-A1 | SUBSTITUTED PYRIDIZINONE DERIVATIVES AS PDE10 INHIBITORS | PDE12, PDE5A, PDE10A | LMNA 4012/4885GAA 444/4885HSD17B10 89/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.